Cogent Biosciences shares are trading higher ...

robot
Abstract generation in progress

Cogent Biosciences (NASDAQ:COGT) shares are trading higher following the FDA’s approval of its new drug application for bezuclastinib. The drug is intended for patients with non-advanced systemic mastocytosis. This headline-only article highlights real-time intelligence for traders.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments